---
title: "PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295660067.md"
description: "The FDA has agreed to review the New Drug Application (NDA) for D-PLEX100 with priority status. The Prescription Drug User Fee Act (PDUFA) goal date is set for November 28, 2026, about three months earlier than originally expected."
datetime: "2026-08-12T11:32:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295660067.md)
  - [en](https://longbridge.com/en/news/295660067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295660067.md)
generator: "portal-rs"
---

# PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

The FDA has agreed to review the New Drug Application (NDA) for D-PLEX100 with priority status. The Prescription Drug User Fee Act (PDUFA) goal date is set for November 28, 2026, about three months earlier than originally expected.

### Related Stocks

- [PYPD.US](https://longbridge.com/en/quote/PYPD.US.md)

## Related News & Research

- [PolyPid Ltd. (NASDAQ:PYPD) Sees Large Drop in Short Interest](https://longbridge.com/en/news/297431820.md)
- [PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential](https://longbridge.com/en/news/293345524.md)
- [PolyPid (PYPD) Q2 2026 Earnings Call: D-PLEX100 Priority Review and Azurity Deal](https://longbridge.com/en/news/295904620.md)
- [PolyPid says FDA accepts D-PLEX100 NDA, grants priority review](https://longbridge.com/en/news/294208202.md)
- [China Shenhua posts 2026 interim report and interim financial report](https://longbridge.com/en/news/297327331.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**